MARK2抗体;MARK2 Antibody—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: A431 and Raji cell lysates, Primary antibody: P13176(MARK2 Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13176(MARK2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

**Background of MARK2 Antibody**

MARK2 (Microtubule Affinity-Regulating Kinase 2), also known as PAR1b, is a serine/threonine kinase belonging to the AMPK-related kinase family. It plays a critical role in regulating microtubule dynamics and cell polarity by phosphorylating microtubule-associated proteins (e.g., tau, MAP2/4), destabilizing their interaction with microtubules. MARK2 is involved in diverse cellular processes, including neuronal development, cell division, and signal transduction. Dysregulation of MARK2 has been linked to neurological disorders (e.g., Alzheimer’s disease, where hyperphosphorylated tau forms neurofibrillary tangles) and cancer (e.g., influencing cell migration and metastasis).

MARK2 antibodies are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect MARK2 in tissues or cultured cells. Specific antibodies can distinguish phosphorylated or isoform-specific forms, aiding research into MARK2’s role in disease mechanisms or therapeutic targeting. Commercial MARK2 antibodies are typically validated for specificity using knockout controls or siRNA-mediated knockdown. Ongoing research focuses on clarifying MARK2’s interplay with other polarity regulators (e.g., LKB1 kinase) and its potential as a biomarker or drug target in neurodegeneration and oncology.